🔍

Panchsheel Organics Ltd (531726)

📊 BSE: 531726 🏢 Pharmaceuticals 📢 Latest filing: 31 Aug 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Panchsheel Organics' revenue was ₹24.7 Cr (+4.7% year on year, -20.6% on the previous quarter), and net profit ₹2.3 Cr (-18.9% year on year); the operating margin was 13.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹24.7	+4.7%	-20.6%
Operating profit	₹3.3	-11.1%	+37.1%
Net profit	₹2.3	-18.9%	+36.0%
EPS (₹)	1.76	-18.5%	+36.4%
Operating margin	13.5%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Panchsheel Organics Board to Meet on Sep 8, 2026 to Approve AGM Details & Dividend Record Date

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 31 Aug 2026, 07:31 PM

Panchsheel Organics Ltd has scheduled a meeting of its Board of Directors on September 8, 2026. The board will consider and approve the annual reports (Board's Report, Corporate Governance, and MD&A) for the financial year ended March 31, 2026, and finalize arrangements for the 37th Annual General Meeting (AGM). The agenda also includes setting the cut-off date for remote e-voting and fixing the Dividend Record Date and Book Closure Date.

Board meeting scheduled for Tuesday, September 8, 2026, at 03:00 PM.
Agenda includes approval of Annual Report, Corporate Governance Report, and MD&A for FY26.
Board to fix the date, venue, and notice for the 37th Annual General Meeting.
Board to fix the Dividend Record Date and Book Closure Date alongside e-voting cut-off dates.

💡 Track the exchange outcome on September 8, 2026, for the final AGM schedule and dividend record date.

Panchsheel Organics Appoints Kishor Turakhia as Managing Director for a 5-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 14 Aug 2026, 04:50 PM

Panchsheel Organics has approved the change in designation of promoter Mr. Kishor Abhaychand Turakhia from Whole-time Director to Managing Director for a 5-year tenure effective August 14, 2026, subject to shareholder approval. Mr. Turakhia brings over 40 years of experience in the pharmaceutical industry and finance and personally holds 21,21,772 equity shares in the company. The leadership transition follows the demise of director Shri Mahendra A. Turakhia, maintaining promoter management continuity. The company reported revenue of Rs 24.67 Cr and net profit of Rs 2.31 Cr in the June 2026 quarter.

Appointment tenure is set for 5 years effective August 14, 2026, subject to shareholder approval
Appointee Mr. Kishor Abhaychand Turakhia holds 21,21,772 equity shares in the company
Brings over 40 years of experience in pharmaceuticals and finance to lead growth strategies

💡 Monitor shareholder approval voting at the upcoming General Meeting and execution on growth projects.

Panchsheel Organics Redesignates Promoter Kishor Turakhia as Managing Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 14 Aug 2026, 04:47 PM

Panchsheel Organics Limited has approved the re-designation of promoter Kishor Abhaychand Turakhia from Whole-time Director to Managing Director effective August 14, 2026. The appointment is for a tenure of 5 years and is subject to shareholder approval at the upcoming General Meeting. Mr. Turakhia possesses over 40 years of experience in the pharmaceutical and finance sectors and holds 21,21,772 equity shares in the company. Since this is an internal re-designation of an existing executive director, operational continuity is expected to remain unaffected.

Re-designation of Mr. Kishor Abhaychand Turakhia from Whole-time Director to Managing Director effective August 14, 2026
Appointed for a tenure of 5 years, subject to shareholder approval
Executive brings more than 40 years of pharmaceutical industry and finance experience
Holds 21,21,772 equity shares in the company as a promoter

💡 Track voting resolutions at the upcoming Annual/Extraordinary General Meeting for formal shareholder approval of the appointment and remuneration terms.

Panchsheel Organics Declares ₹0.80/Share Interim Dividend; Record Date Set in August 2026

🟢 POSITIVE ⭐ 5/10

DIVIDEND 📅 14 Aug 2026, 04:37 PM

Panchsheel Organics Limited has declared an interim dividend of ₹0.80 per equity share (face value ₹10 each) for the quarter ended June 30, 2026 (FY 2026-27), representing 8% of paid-up share capital. The dividend declaration follows Q1 FY27 net profit of ₹2.31 crore and an EPS of ₹1.76. The company fixed the record date as August 21, 2026 to determine eligible shareholders. The dividend payout is scheduled to be completed within 30 days of declaration.

Interim dividend of ₹0.80 per equity share declared for Q1 FY27
Dividend rate stands at 8% of the paid-up face value of ₹10 per share
Record date fixed for August 21, 2026 for dividend entitlement
Dividend distribution will be completed within 30 days of declaration

💡 Track the ex-dividend date prior to the August 21, 2026 record date for entitlement, and monitor payment execution within the 30-day statutory window.

Panchsheel Organics Declares ₹0.80 Interim Dividend; Appoints New MD

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 14 Aug 2026, 04:32 PM

Panchsheel Organics has declared an interim dividend of ₹0.80 per equity share (face value ₹10) for the quarter ended June 30, 2026. The board has fixed August 21, 2026, as the record date, with dividend disbursement scheduled on or before September 13, 2026. Against a Q1 FY27 net profit of ₹2.31 crore and EPS of ₹1.76, the ₹0.80 per share dividend represents a quarterly payout ratio of approximately 45.5%. Additionally, following the demise of ex-MD Mahendra Turakhia, the board appointed Whole-time Director Kishor Abhaychand Turakhia as Managing Director for a 5-year term.

Interim dividend declared at ₹0.80 per equity share (8% of ₹10 face value)
Record date set for August 21, 2026; payment on or before September 13, 2026
Kishor Abhaychand Turakhia redesignated as Managing Director for a 5-year term (holds 21,21,772 shares)
Mrs. Chandan Mahendra Turakhia appointed as Additional Non-Executive Director
Demise of ex-Managing Director Mahendra Abhaychand Turakhia recorded effective August 1, 2026

💡 Track the record date of August 21, 2026, for dividend eligibility, and monitor upcoming shareholder voting on the appointment of the new Managing Director.

Panchsheel Organics Declares Rs 0.80 Interim Dividend; Appoints New Managing Director

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 14 Aug 2026, 04:29 PM

Panchsheel Organics approved its Q1 unaudited financial results for the quarter ended June 30, 2026, and declared an interim dividend of Rs 0.80 per equity share (face value Rs 10). The record date for the interim dividend is fixed for August 21, 2026, with payment on or before September 13, 2026. Following the sad demise of ex-Managing Director Mr. Mahendra Abhaychand Turakhia on August 1, 2026, the board approved the elevation of Whole-time Director Mr. Kishor Abhaychand Turakhia as Managing Director for a 5-year term. Additionally, Mrs. Chandan Mahendra Turakhia was inducted as an Additional Non-Executive Director.

Interim dividend of Rs 0.80 per equity share (8% on face value of Rs 10) declared for Q1 FY27
Record date set for August 21, 2026; dividend payout scheduled on or before September 13, 2026
Mr. Kishor Abhaychand Turakhia redesignated as Managing Director for a 5-year term
Mrs. Chandan Mahendra Turakhia appointed as Additional Non-Executive Director effective August 14, 2026

💡 Monitor the ex-dividend date ahead of August 21, 2026, and observe execution under the elevated leadership team in forthcoming quarters.

₹0.80 Interim Dividend declared; Management transition following MD's demise

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 14 Aug 2026, 04:23 PM

Panchsheel Organics has declared an interim dividend of ₹0.80 per share (8% of face value) for Q1 FY27, with a record date of August 21, 2026. The company is undergoing a leadership transition following the passing of Managing Director Mr. Mahendra Abhaychand Turakhia on August 1, 2026. Mr. Kishor Abhaychand Turakhia, a promoter with over 40 years of experience, has been elevated to Managing Director for a 5-year term. Additionally, Mrs. Chandan Mahendra Turakhia has been appointed as an Additional Non-Executive Director.

Interim dividend of ₹0.80 per share declared for the quarter ended June 30, 2026.
Record date for dividend entitlement fixed as August 21, 2026, with payment by September 13, 2026.
Mr. Kishor Abhaychand Turakhia appointed as Managing Director for a 5-year term effective August 14, 2026.
Transition follows the demise of former MD Mr. Mahendra Abhaychand Turakhia on August 1, 2026.
Mrs. Chandan Mahendra Turakhia appointed as Additional Non-Executive Director.

💡 Investors should monitor the upcoming Q1 FY27 financial results for operational performance and track the new Managing Director's progress on the fermentation plant expansion mentioned in previous strategies.

Aug 14 Board Meeting: Q1 Results and Interim Dividend Consideration

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 07 Aug 2026, 06:39 PM

Panchsheel Organics has scheduled a board meeting for August 14, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The board will also consider the declaration of an interim dividend for the first quarter of FY27. Additionally, the company will appoint M/s Ritesh Talati & Associates as Cost Accountants and formally note the cessation of directorship of the late Shri Mahendra A. Turakhia. This follows a fiscal year (FY26) where the company maintained revenue at Rs 107 Cr but saw a decline in net profit to Rs 11 Cr from Rs 14 Cr in FY25.

Board meeting scheduled for August 14, 2026, at 03:00 p.m. in Mumbai
Agenda includes consideration and approval of an interim dividend for Q1 FY27
Appointment of M/s Ritesh Talati & Associates as the company's Cost Accountant
Formal note of the cessation of directorship for Late Shri Mahendra A. Turakhia
Trading window remains closed from July 01, 2026, until 48 hours post-result declaration

💡 Monitor the August 14 results to evaluate if the new fermentation plant has begun contributing to revenue and if operating margins (13% in FY26) show signs of recovery.

Board Meeting on Aug 14 to Approve Q1 Results and Consider Interim Dividend

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 07 Aug 2026, 05:51 PM

Panchsheel Organics has scheduled a board meeting for August 14, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. Significantly, the board will also consider the declaration of an interim dividend for the first quarter of FY27. This follows a fiscal year (FY26) where the company maintained flat revenue of ₹107 Cr but saw a decline in net profit to ₹11 Cr from ₹14 Cr in FY25. The meeting will also address the appointment of a new Cost Accountant and note a change in the board composition due to the passing of a director.

Board meeting scheduled for August 14, 2026, to approve Q1 FY27 financial results
Board to consider and approve an interim dividend for the quarter ended June 30, 2026
Appointment of M/s Ritesh Talati & Associates as the company's Cost Accountant is on the agenda
Formal note of the cessation of directorship of Late Shri Mahendra A. Turakhia
Trading window remains closed from July 01, 2026, until 48 hours after the results declaration

💡 Monitor the Q1 FY27 results on August 14 to check if the new fermentation plant has started contributing to revenue, as the company previously targeted a 5.79% growth rate.

Demise of Managing Director and Promoter holding 16.10% stake

🔴 NEGATIVE ⭐ 8/10

MANAGEMENT 📅 03 Aug 2026, 11:31 PM

Panchsheel Organics has announced the unexpected demise of its Managing Director and Promoter, Mr. Mahendra Abhaychand Turakhia, on August 01, 2026. Mr. Turakhia held 21,20,672 shares, representing 16.10% of the company's total equity. Given the company's small-cap size (Rs 154 Cr) and his role as MD, this represents a significant loss in leadership. Investors should monitor the board's upcoming decision regarding a successor to lead the company's ongoing expansion projects.

Demise of Managing Director and Promoter Mr. Mahendra Abhaychand Turakhia on August 01, 2026
Deceased held 21,20,672 shares, equivalent to 16.10% of the company
The deceased's stake accounts for approximately 28.7% of the total promoter holding (56.12%)
Company is currently in the process of expanding via a new fermentation plant as of FY25

💡 Monitor the exchange filings for the appointment of a new Managing Director and any updates regarding the transmission of the 16.10% shareholding to legal heirs.

View All 531726 Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment (Bulk Drugs). Total income grew by 2.39% YoY, reaching INR 110.25 Cr in FY25 compared to INR 107.68 Cr in FY24. Domestic sales grew 1.8% to INR 105.80 Cr, while export sales saw a marginal increase of 0.27% to INR 1.29 Cr.

Geographic Revenue Split

Domestic sales dominate the revenue profile, contributing approximately 98.8% (INR 105.80 Cr) of total sales in FY25. Export sales to over 15 countries contribute the remaining 1.2% (INR 1.29 Cr).

Profitability Margins

Net Profit Margin for FY25 stood at 12.51% (INR 13.79 Cr PAT on INR 110.25 Cr income). In Q2 FY24, PAT margins were 15.55%, an improvement from 15.10% in Q2 FY23, driven by stable operational performance despite rising costs.

EBITDA Margin

EBITDA margin for Q2 FY24 was 18.68% (INR 4.43 Cr), a decrease from 21.80% in Q2 FY23. For H1 FY24, EBITDA margin was 19.24% (INR 9.30 Cr), down from 22.62% YoY, primarily due to an 8.7% increase in operating expenditures.

Capital Expenditure

The company is investing in a state-of-the-art fermentation plant scheduled for Q1 FY25. As of Q2 FY24, 50% of civil work was completed. Property, Plant, and Equipment (PPE) stood at INR 8.21 Cr as of September 2023, with Capital Work-in-Progress (CWIP) at INR 4.21 Cr.

Credit Rating & Borrowing

The company holds a 'CRISIL BBB-/Stable' rating (reaffirmed May 2025). Borrowing costs are low, with finance charges of INR 0.37 Cr in FY25. The company maintains a healthy interest coverage ratio of 50.25x and a gearing ratio of 0.03x.

⚙️ Operational Drivers

Raw Materials

Key raw materials include petroleum-based products, various Active Pharmaceutical Ingredients (APIs), and chemical intermediates. These materials are critical for the bulk drug manufacturing process.

Import Sources

A significant portion of APIs and intermediates are sourced from China. The company also leverages its strategic location in Indore, Madhya Pradesh, for domestic sourcing of utilities and raw materials.

Key Suppliers

Specific supplier names are not disclosed, but the company relies heavily on Chinese manufacturers for intermediates, which exposes it to supply chain disruptions.

Capacity Expansion

Current facilities include a 7,500 sq. mt. API plant in Indore with four manufacturing blocks (5,000 sq. mt.). Expansion includes the first state-of-the-art fermentation plant, with 50% civil construction completed as of late 2023.

Raw Material Costs

Operating expenditure, largely driven by raw materials, rose 8.7% to INR 83.32 Cr in FY25. Raw material prices for APIs and intermediates have risen significantly due to production restrictions in China and inflationary pressures on petroleum-based products.

Manufacturing Efficiency

The company maintains GMP and WHO standards. Manufacturing efficiency is supported by a strong R&D setup and a 35-year track record in the industry.

Logistics & Distribution

Distribution costs are impacted by fluctuations in freight and forwarding charges, which the company identifies as a key factor affecting results of operations.

📈 Strategic Growth

Expected Growth Rate

5.79%

Growth Strategy

Growth will be achieved through the launch of the new fermentation plant in Q1 FY25, expanding the product portfolio in domestic and international markets (15+ countries), and leveraging long-term relationships with major clients like Abbott and Zydus.

Products & Services

Active Pharmaceutical Ingredients (APIs), chemical intermediates, and finished pharmaceutical formulations.

Brand Portfolio

Panchsheel Organics Limited; Turakhia Bros Group.

New Products/Services

The upcoming fermentation plant will introduce new fermentation-based products, expected to contribute to revenue starting FY25.

Market Expansion

The company is continuously tapping new international markets, currently exporting to more than 15 countries, and strengthening its niche in the domestic specialty chemicals market.

Strategic Alliances

The company maintains a reputed clientele including Abbott, Ajanta Pharma, and Zydus, which serves as a stable revenue base.

🌍 External Factors

Industry Trends

The global pharmaceutical industry is projected to grow, with retail drug spending at ~9% of NHE. The industry is shifting toward more resilient supply chains and sustainability, with POL positioning itself through its new fermentation capabilities.

Competitive Landscape

Faces intense competition from local regional players in the unorganized sector and large global bulk drug manufacturers.

Competitive Moat

Moat is built on a 35-year track record, state-of-the-art Indore manufacturing facility, and established relationships with Tier-1 pharma companies. This is sustainable due to high regulatory barriers (GMP/WHO) in API manufacturing.

Macro Economic Sensitivity

Highly sensitive to global inflationary conditions and petroleum price hikes, which increase the cost of raw materials and logistics.

Consumer Behavior

Rising demand for life-saving drugs at economical prices is driving the need for efficient API manufacturing.

Geopolitical Risks

Geo-political conflicts and trade barriers, particularly involving China, pose significant risks to the supply of essential intermediates.

⚖️ Regulatory & Governance

Industry Regulations

Operations must comply with GMP, WHO standards, and ISO 9001:2008. The company is also subject to environmental standards and changes in tax laws.

Environmental Compliance

The company maintains a sustainability and compliance framework to meet environmental standards, though specific ESG costs are not disclosed.

Taxation Policy Impact

Effective tax rate for FY25 was approximately 25.7% (INR 4.66 Cr tax on INR 18.10 Cr PBT).

Legal Contingencies

Pending tax litigations with the MP Commercial Tax Appellate Board (Bhopal) include cases for FY13 (INR 22.35 Lakhs), FY14 (INR 0.58 Lakhs), FY15 (INR 4.52 Lakhs), and FY17 (INR 3.32 Lakhs). Total pending tax matters are approximately INR 30.77 Lakhs.